BETHLEHEM, Pa., Feb. 07, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2022 fourth quarter financial results and certain business developments for 5:00 pm ET (2:00 pm PT) on Tuesday, February 14, 2023.
February 14, 2023 schedule:
4:05 p.m. ET – 2022 fourth quarter financial results press release will be distributed.
Prior to the call - To participate in the teleconference, go to the following link to register and the teleconference number and PIN for the teleconference will be sent to you:
https://register.vevent.com/register/BIf712ba49243f46c7a741f490d1ea19a4
5:00 p.m. ET - Conference call and simultaneous webcast begins.
The conference call will also be available via webcast, and may be accessed on the investor relations page of OraSure’s website, www.orasure.com. Please click on the webcast link and follow the prompts for registration and access, 10 minutes prior to the call.
If you are unable to participate, the webcast will be archived on OraSure’s website shortly after the call has ended and will be available for 14 days.
| Investor Contact: Scott Gleason SVP Investor Relations & Corporate Communications Communications 484-425-0588 This email address is being protected from spambots. You need JavaScript enabled to view it. | Media Contact: Amy Koch Sr. Mgr. Corporate Communications 484-523-1815 This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$3.04 |
| Daily Change: | -0.01 -0.33 |
| Daily Volume: | 630,708 |
| Market Cap: | US$227.390M |
February 25, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
